MetLife Investment Advisors LLC decreased its position in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 35.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,537 shares of the company’s stock after selling 22,358 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Amneal Pharmaceuticals were worth $548,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Amneal Pharmaceuticals by 28.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock worth $91,000 after acquiring an additional 1,477 shares during the last quarter. Bessemer Group Inc. bought a new position in Amneal Pharmaceuticals during the 4th quarter worth approximately $34,000. JPMorgan Chase & Co. lifted its stake in Amneal Pharmaceuticals by 12.8% in the third quarter. JPMorgan Chase & Co. now owns 24,155 shares of the company’s stock valued at $536,000 after buying an additional 2,739 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Amneal Pharmaceuticals by 14.9% in the third quarter. Hsbc Holdings PLC now owns 28,613 shares of the company’s stock valued at $635,000 after buying an additional 3,706 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Amneal Pharmaceuticals by 30.4% in the fourth quarter. Principal Financial Group Inc. now owns 16,485 shares of the company’s stock valued at $223,000 after buying an additional 3,843 shares in the last quarter. 38.90% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have weighed in on AMRX. ValuEngine lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. SunTrust Banks began coverage on shares of Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 price target on the stock. Zacks Investment Research lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 14th. Leerink Swann lowered shares of Amneal Pharmaceuticals to a “market perform” rating in a research note on Friday, March 8th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $35.00 price target on shares of Amneal Pharmaceuticals in a research note on Thursday, February 28th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $20.80.

In other news, insider Paul Bisaro bought 17,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were acquired at an average cost of $11.97 per share, for a total transaction of $203,490.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Peter R. Terreri sold 23,345 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $12.39, for a total transaction of $289,244.55. The disclosure for this sale can be found here. 26.34% of the stock is owned by company insiders.

NYSE AMRX opened at $13.72 on Wednesday. The company has a debt-to-equity ratio of 2.98, a quick ratio of 1.50 and a current ratio of 2.32. Amneal Pharmaceuticals Inc has a 12-month low of $11.63 and a 12-month high of $24.48. The company has a market capitalization of $4.18 billion, a PE ratio of 14.44, a price-to-earnings-growth ratio of 0.64 and a beta of 1.37.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Thursday, February 28th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.06. Amneal Pharmaceuticals had a net margin of 1.84% and a return on equity of 25.73%. The company had revenue of $497.53 million for the quarter, compared to the consensus estimate of $478.06 million. On average, analysts predict that Amneal Pharmaceuticals Inc will post 0.98 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/amneal-pharmaceuticals-inc-amrx-position-trimmed-by-metlife-investment-advisors-llc/2952499.html.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.